A 26-Week,Randomised,Open-Label,Multicenter,Active-Controlled,Parallel-Design,Phase III Clinical Trial to Compare the Efficacy and Safety of Insulin Degludec/Liraglutide Injection With XULTOPHY® Once Daily Via Subcutaneous Injection in Chinese Subjects With Type 2 Diabetes
Phase 3 trial compares Chinese-manufactured insulin degludec/liraglutide combination to Novo Nordisk's Xultophy in adults with type 2 diabetes. Open-label study targets 510 participants over 26 weeks with HbA1c reduction as primary endpoint, expected completion October 2025. Tonghua Dongbao tests its biosimilar combination against the established Novo Nordisk product in the Chinese market. This represents China's push toward domestic alternatives in the GLP-1/insulin combination space.